Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
LG1M is Prognostic for Long-Term Readmission After AKI
May 23, 2024
The novel fibrosis biomarker LG1M is prognostic for long-term readmission after AKI
Introduction
Acute Kidney Injury (AKI), survivors are at increased risk of long-term adverse outcomes, including readmission to hospital. Pathophysiological consequences of AKI, include extracellular matrix (ECM) remodeling. Tools to monitor the long-term health risk of patients after AKI are needed to improve
patient outcome.
Poster
Conclusion
Circulating levels of LG1M were elevated in AKI patients 1 year after the AKI episode and correlated with markers of kidney function in the AKI group and to a lower extent in the CKD control group. In the AKI group, LG1M was associated with the risk of readmission, even though the significance of the association was lost in adjusted analyses. This biomarker, quantifying circulating levels of a laminin fragment, may reflect injury to the basement membrane (of which laminin is a major component) after AKI, which was associated with an increased risk of worse outcome in patients that experienced an episode of AKI.
